DETAILED ACTION
1. Claims 1-3, 5-6, 10-13, 15, 23, 25-26, 28-29, 36-38, 54 are pending in the instant application.
2. The rejection of claim 37 under 35 U.S.C. 112, second paragraph is withdrawn in view of applicant’s amendment and argument in paper dated on 08/12/2026.
3. The rejection of claims 36-38, 54 under 35 U.S.C. 112, first paragraph is withdrawn in view of applicant’s amendment and argument in paper dated on 08/12/2026.
4. The rejection of claims 1-3, 5-6, 10-13, 15, 23, 25-26, 28-29, 36-38, 54 under 35 U.S.C. 102(a)(1) over Filler et al., Journal of the Chemical Society [section] C: organic (1971), (11), 2062-8 is maintained for reason of record.
Applicants argue that Filler discloses various reactions of polyfluoroaromatic compounds. Neither does Filler disclose combining hydrazine dimers with pharmaceutically acceptable carriers or using hydrazine dimers to treat psychological disorders.
It is Examiners position that Filler discloses the instant claimed compound as follows:
PNG
media_image1.png
276
490
media_image1.png
Greyscale
. The above compound can be used as antidepressant drugs and treat psychological disorder. Therefore, the above compound can be in pharmaceutical composition form. Therefore, using the above compound as a pharmaceutical composition is inherently there.
5. The rejection of claims 1-3, 5-6, 10-13, 15, 23, 25-26, 28-29 under 35 U.S.C. 102(a)(1) and 102(a)(2) over Arashi et al., US 3959343 is maintained for reason of record.
Applicants argue that Arashi discloses a “process for producing hydrazonitriles” using ketazines such as RN 18300-79-3 as intermediates in the manufacture of azonitriles for use as polymerization initiators and blowing agents.
It is Examiners position that Arashi discloses the instant claimed compound as follows:
PNG
media_image2.png
154
314
media_image2.png
Greyscale
. The above compound can be used as a pharmaceutical composition form. Therefore, using the above compound as a pharmaceutical composition is inherently there.
6. The rejection of claims 1-3, 5-6, 10-13, 15, 23, 25-26, 28-29 under 35 U.S.C. 102(a)(1) over Toyota et al., Heteroatom Chemistry (2001), 12(5), 418-423 is maintained for reason of record.
Applicants argue that Toyota is directed to NMR studies. As such, Toyota does not disclose the recited claim limitations of a “therapeutically effective amount,” and “a pharmaceutically acceptable carrier,” or treatment o “a psychological disorder.”
It is Examiners position that Filler discloses the instant claimed compound as follows:
PNG
media_image3.png
226
424
media_image3.png
Greyscale
. The above compound can be used in pharmaceutical composition form. Therefore, using the above compound as a pharmaceutical composition is inherently there.
7. The rejection of claims 1-3, 5-6, 10-13, 15, 23, 25-26, 28-29 under 35 U.S.C. 102(a)(1) over Xu et al., Acta Crystallographica, section E: structure reports online (2009), 65(12), m1559-m1560 is maintained for reason of record.
Applicants argue that Xu is directed to spectroscopic studies.
It is Examiners position that Filler discloses the instant claimed compound as follows:
PNG
media_image3.png
226
424
media_image3.png
Greyscale
. The above compound can be used in pharmaceutical composition form. Therefore, using the above compound as a pharmaceutical composition is inherently there.
8. The rejection of claims 1-3, 5-6, 10-13, 15, 23, 25-26, 28-29 under 35 U.S.C. 102(a)(1) over Nodzewska et al., Science of synthesis, knowledge updates (2012), (3), 445-463 is maintained for reason of record.
Applicants argue that Nodzewska discloses methods of azine synthesis.
It is Examiners position that Filler discloses the instant claimed compound as follows:
PNG
media_image4.png
156
448
media_image4.png
Greyscale
. The above compound can be used in pharmaceutical composition form. Therefore, using the above compound as a pharmaceutical composition is inherently there.
THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicants are reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for replying to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.
9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Niloofar Rahmani whose telephone number is
571-272-4329. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor, can be reached on 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
/NILOOFAR RAHMANI/ Primary Examiner, Art Unit 1691 08/25/2026
Prosecution Insights